Head to Head Comparison: Halozyme Therapeutics (NASDAQ:HALO) & Iovance Biotherapeutics (NASDAQ:IOVA)

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Halozyme Therapeutics and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 26.93% 751.81% 23.84%
Iovance Biotherapeutics -58.20% -29.71% -23.55%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Halozyme Therapeutics and Iovance Biotherapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 5 7 0 2.46
Iovance Biotherapeutics 1 3 9 1 2.71

Halozyme Therapeutics presently has a consensus price target of $108.18, suggesting a potential upside of 11.64%. Iovance Biotherapeutics has a consensus price target of $13.80, suggesting a potential upside of 85.38%. Given Iovance Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Halozyme Therapeutics.

Risk and Volatility

Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

Earnings and Valuation

This table compares Halozyme Therapeutics and Iovance Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Halozyme Therapeutics $1.40 billion 7.91 $316.89 million $3.93 24.66
Iovance Biotherapeutics $263.50 million 13.07 -$390.98 million ($0.53) -14.05

Halozyme Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics beats Iovance Biotherapeutics on 9 of the 15 factors compared between the two stocks.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.